Denileukin diftitox Product Approval Information - Licensing Action

Proper name: Denileukin diftitox
Tradename: Ontak
Manufacturer: Seragen, Inc, Hopkinton, MA, License #1258
Indication for Use: Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor
Approval Date: 2/5/99
Type of submission: Biologics license application


Approval Letter (PDF)

Label (PDF)




Clinical - (PDF)  Part C
Clinical Pharmacology (PDF)
Pharmacology (PDF)
Statistical (PDF)


Page Last Updated: 05/16/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English